Physician profile
Maryam Shambayati
NPI 1235486416
$269,033.64
in general payments reported to CMS, 2019-2025
30 companies · $84K in 2025
The $84K reported for 2025 was more than what 99% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $18K · 2021: $18K · 2022: $28K · 2023: $57K · 2024: $42K · 2025: $84K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $131K · Honoraria: $19K · Travel and Lodging: $16K · Consulting Fee: $8,876 · Food and Beverage: $7,678 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $131,089.86 |
| Honoraria | $19,050.00 |
| Travel and Lodging | $16,082.41 |
| Consulting Fee | $8,875.50 |
| Food and Beverage | $7,678.32 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $71,498.82 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $62,940.99 | 2020-2025 | Gattex, Eohilia |
| Genzyme Corporation | $56,433.12 | 2022-2025 | |
| Abbvie INC. | $42,763.97 | 2019-2024 | Rinvoq |
| Regeneron Healthcare Solutions, INC. | $23,860.14 | 2022-2025 | Dupixent |
| Pfizer INC. | $6,204.12 | 2019-2023 | |
| Janssen Biotech, INC. | $1,803.27 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Janssen Scientific Affairs, LLC | $1,476.79 | 2020-2025 | Stelara, Tremfya, Simponi |
| Madrigal Pharmaceuticals | $495.11 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $243.61 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.38 | 2019 | |
| Alcresta Therapeutics, INC. | $187.01 | 2023-2024 | Relizorb |
| Gilead Sciences, INC. | $178.93 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $150.22 | 2024-2025 | Bylvay, Iqirvo |
| Aimmune Therapeutics, INC. | $113.96 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $92.22 | 2024 | |
| Intercept Pharmaceuticals, INC. | $57.98 | 2019 | |
| Coloplast Corp | $48.64 | 2020-2025 | |
| Amgen INC. | $47.42 | 2019-2023 | Avsola, Amjevita |
| Avanos Medical | $35.16 | 2023 | Mic-Key |
| Eisai INC. | $35.03 | 2022 | |
| Novo Nordisk INC | $30.02 | 2019-2025 | Wegovy |
| Shire North American Group INC | $24.58 | 2019 | |
| Biocon Biologics INC | $21.75 | 2025 | Yesintek |
| Albireo Pharma, INC. | $19.62 | 2022 | |
| Amneal Pharmaceuticals LLC | $15.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.78 | 2024 | Cyltezo |
| Capsovision, INC. | $14.61 | 2025 | Capsocam Plus |
| Applied Medical Technology INC | $12.80 | 2022 | |
| Alexion Pharmaceuticals, INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryam Shambayati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.